Clinical Research Manager
Psychiatry and Behavioral Sciences
Baylor College of Medicine
Houston, Texas, United States


BS from University of Houston


Central Texas Phlebotomy Institute, LLC


HDE DBS Therapy: Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder
Approved by the FDA under Humanitarian Device Exemption (HDE) guidelines, this protocol allows for the use of DBS as a treatment for severe, treatment-resistant OCD in adult patients who have failed at least 3 SRIs and have been unable to complete an adequate trial of CBT. We collect safety data from this HDE to enhance our knowledge of the risks and benefits of this device.
*This is not a research protocol*
A Clinical Pilot Study Examining Bilateral Inhibition of the Lateral Habenula as a Target for Deep Brain Stimulation in Intractable Depression
This pilot study investigates the safety, tolerability, and benefit of bilateral Deep Brain Stimulation (DBS) to the lateral habenula in subjects with treatment-resistant major depression (TRD). Increased activity in the lateral habenula has been associated with an animal models of "irreversible helplessness", and it is suspected that inhibitory stimulation to this brain structure may reduce depressive symptoms in humans. Participants in this study will be implanted with a DBS device and followed for at least 18 months to access treatment efficacy and outcomes.
Development of Adaptive Deep Brain Stimulation (aDBS) for the Treatment of Intractable Obsessive Compulsive Disorder (OCD)
The goal of this clinical trial is to gather data to classify OCD symptoms and other mood states in order to develop an adaptive Deep Brain Stimulation system (aDBS), which can automatically adjust stimulation as needed to control OCD symptoms, based on the individual's changing needs. Participants must have severe, treatment-resistant OCD, have failed at least 3 SSRIs, an augmentation with an antipsychotic, a trail of Clomipramine, and an adequate trial of CBT. Eligible participants will be implanted with a DBS device and followed for at least 18 months.
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive BHV-4157 in Obsessive Compulsive Disorder
This is a Phase IIb/III, multicenter, randomized, double-blind, placebo-controlled, 2-arm clinical trial to assess safety, tolerability, and efficacy of troriluzole as an adjunctive therapy in subjects with Obsessive Compulsive Disorder (OCD). Troriluzole is a novel glutamate modulating drug that can be taken along with standard of care medications for OCD. Participants must have a diagnosis of OCD and currently be taking an SSRI or Clomipramine. Participation is 12 weeks long, with the option to enter an extension phase for an additional 48 weeks.
Measuring Automated Behavioral Observations and Vocal Expressions (ABOVE) While Recording from the Brain
ABOVE is an observational study with the goal to better understand the relationships between brain activity and OCD behaviors. In this study we capture video recordings of head, body, and face dynamics of OCD and control participants during tasks designed to provoke social anxiety and OCD-related anxiety. Recruitment is focused on OCD participants with contamination-related obsessions in order to further analyze face/body dynamics during hand-washing behaviors performed in the clinic, compared to controls.